share_log

B of A Securities Maintains Buy on Turnstone Biologics, Lowers Price Target to $10

B of A Securities Maintains Buy on Turnstone Biologics, Lowers Price Target to $10

B of A Securities維持對Turnstone生物製品的買入評級,將目標價下調至10美元。
Benzinga ·  08/19 12:46  · 評級/大行評級

B of A Securities analyst Geoff Meacham maintains Turnstone Biologics (NASDAQ:TSBX) with a Buy and lowers the price target from $12 to $10.

B of A證券分析師Geoff Meacham認爲Turnstone Biologics(NASDAQ:TSBX)值得買入,並將目標價從$12降至$10。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論